22nd Oct 2021 – Las Vegas, NV (October 22nd, 2021) – Evolve presented updated results on behalf of Dr Richard Wasserman from the completed PlasmaCap IG Phase III Clinical Trial entitled “Efficacy and Safety of PlasmaCap IG, a New 10% Intravenous Immunoglobulin Manufactured Using an Innovative Chromatography Process, In Adults and Children with Primary Immunodeficiency Disorders”